Milner Institute welcomes local MPs to explore research and innovation
Last week, we were delighted to welcome Pippa Heylings MP, Charlotte Cane MP and Councillor Olaf Hauk to the Milner Therapeutics Institute. The visit provided an opportunity to showcase our mission and impact, including our pioneering research, collaborations with...
Milner Head of AI expands role across Milner Institute and Yonsei University
We are delighted to share that Dr Namshik Han, Head of AI and Computational Research at the Milner Therapeutics Institute, has begun a new role as Professor at Yonsei University in Seoul, South Korea. Namshik will divide his time between Yonsei University and the...
Milner Institute announced as finalist for 2025 OBN Award
We are delighted to share that the Milner Therapeutics Institute has been announced as a finalist for a 2025 OBN Award in the category of Most Impactful Industry Collaboration! We have been recognised for the Functional Genomics Screening Laboratory (FGSL), a...
Milner Institute connects pioneering science with investment at its 2025 Pitch Day
Last week, we were proud to host our 2025 Pitch Day, bringing together a vibrant mix of biotech innovators, investors, and translational science leaders. The event provided a high-energy platform for emerging companies to showcase bold new approaches across oncology,...
Milner Therapeutics Symposium showcases innovation in translational science
This week, the Milner Therapeutics Institute hosted its annual Symposium – a hybrid event welcoming approximately 500 in-person delegates and 250+ online attendees. Hosted at West Road Concert Hall in Cambridge, UK, the Symposium brings together leading minds from...
Milner Institute prepares for upcoming Therapeutics Symposium and Pitch Day
We are excited for several Milner events taking place across Cambridge next week, including our annual Therapeutics Symposium and Pitch Day. The Milner Therapeutics Symposium will take place on 30 June, and is an opportunity for scientists from academia and industry...
Shift Bioscience identifies novel single-gene target for safer cellular rejuvenation therapeutics
Shift Bioscience, a company based in the Milner Institute Bio-incubator, has published new research identifying a novel, single-gene target for cellular rejuvenation. Capable of reversing cellular aging across multiple cell types, without inducing dangerous...
Milner Institute begins collaboration with Yonsei University for joint research in quantum computing
We were delighted to host a signing ceremony with Yonsei University last week, for a new Memorandum of Understanding (MOU) between our institute at the University of Cambridge, Cambridge Stem Cell Institute, and the Cambridge Centre for AI in Medicine. This agreement...